GlyCosmos Portal

Submissions

Nilotinib-resistant KIT mutants

Summary

Organism

Homo sapiens (human)

Reactome

R-HSA-9669926

PubChem

R-HSA-9669926

Description

Nilotinib is a type II tyrosine kinase inhibitor currently in clinical trials for treatment of KIT-mutant cancers, and shows variable effectiveness against mutations in exon 11, 13, 17 and 18. Nilotinib is ineffective against the gatekeeper mutation T670I (Kissova et al, 2016; Guo et al, 2007; Roberts et al, 2007; Serrano et al, 2019).

Click on a node on the pathway to see its details. Glycoproteins are marked with a glycoprotein icon in their name.

SPV: a JavaScript Signaling Pathway Visualizer, Bioinformatics, 2018

Displaying 1 entry
UniProt ID	Protein Name	Gene Symbol	Pathway Viewer
P10721	Mast/stem cell growth factor receptor Kit	KIT SCFR	view

If you want to check the location of a particular molecule, you can do so by clicking on the "Switching Highlight" button on the page you have navigated to by clicking on "view".

About Release Notes Help Feedback

Click here to visit the beta site.